DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...
DexCom’s fair value price target has been tweaked from US$85.85 to US$86.12 per share, a small shift that still matters if ...
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. If you are wondering whether DexCom's current share price ...
StockStory.org on MSN
Align Technology, QuidelOrtho, DexCom, Insulet, and Omnicell shares are falling, what you need to know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong fourth-quarter 2025 ...
If you are wondering whether DexCom at around US$64 a share looks appealing or expensive, this article breaks down what that price might actually represent for you. The stock has been under pressure ...
DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results